The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
News|Articles|August 30, 2024
Highlights From Psoriasis Awareness Month
Author(s)Kaitlyn Bader, Senior Editor
Throughout the month of August, Dermatology Times covered psoriasis news related to Alumis Inc’s phase 3 trial of ESK-001 for plaque psoriasis, AbbVie’s Science of Skin event, and more.
Advertisement
Advertisement
Psoriasis Awareness Month is celebrated every August to highlight new research, reduce stigmas associated with psoriasis, educate patients about treatment opportunities, and advocate for future enhancements. With more than 125 million patients worldwide affected by psoriasis, clinicians have the opportunity to educate their patients about their skin condition and provide information about new treatments or upcoming clinical trials.1
Related to this article
Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.
Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.
Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.
Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.
This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
Advertisement
Advertisement